Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6237232 | 0.77 | ALDH1A1 (0.38) | ALOX5TSHRGAASMN1; SMN2 | |
| SCHEMBL6241084 | 0.77 | ALDH1A1 (0.38) | ALOX5TSHRGAASMN1; SMN2 | |
| SCHEMBL6827765 | 0.74 | ALOX5 (0.45) | ALOX5EPHX1ADH1CADH1ASMN1; SMN2 | |
| SCHEMBL6235316 | 0.73 | ALOX5 (0.38) | ALOX5EPHX1ADH1CADH1ASMN1; SMN2 | |
| SCHEMBL6236104 | 0.73 | ALDH1A1 (0.36) | TSHRSMN1; SMN2NPSR1 | |
| SCHEMBL22729195 | 0.72 | ALOX5 (0.43) | ALOX5EPHX1ADH1CADH1A | |
| SCHEMBL6242109 | 0.71 | ALOX5 (0.36) | ALOX5EPHX1ADH1CADH1A | |
| SCHEMBL1957147 | 0.69 | ALOX5 (0.41) | ALOX5EPHX1ADH1BADH1CADH1A | |
| SCHEMBL28496043 | 0.67 | ALOX5 (0.39) | ALOX5EPHX1ADH1CADH1ASMN1; SMN2 | |
| SCHEMBL3069635 | 0.67 | ALOX5 (0.39) | ALOX5EPHX1ADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0191735-A2 | Novel oxaluric acid derivatives and pharmaceutical compositions containing them | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1986-08-20 | — | — | EP | claimed |
| CN-100398102-C | Agent for renal failure containing oxaluric acid derivative | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2008-07-02 | — | — | CN | disclosed |
| US-20050245577-A1 | Drug for kidney failure containing oxaluric acid derivative | NIPPON ZOKI PHARMACEUTICALS CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| CN-1681488-A | Agent for renal failure containing oxaluric acid derivative | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2005-10-12 | — | — | CN | disclosed |
| EP-1537866-A1 | DRUG FOR KIDNEY FAILURE CONTAINING OXALURIC ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co. Ltd. (JP) | 2005-06-08 | — | — | EP | disclosed |
| EP-0191735-B1 | NOVEL OXALURIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-09-12 | — | — | EP | disclosed |
| US-4708954-A | DIABETES-ORAL ADMINISTRATION | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1987-11-24 | — | — | US | disclosed |
| EP-0191735-A2 | Novel oxaluric acid derivatives and pharmaceutical compositions containing them | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245577-A1 | Drug for kidney failure containing oxaluric acid derivative | OAT, OTC, OGFRL1 | OPRK1 519/4885ALOX5 860/4885EPHX1 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.